Comparison of Cerecor Inc. (CERC) and Amicus Therapeutics Inc. (NASDAQ:FOLD)

We are contrasting Cerecor Inc. (NASDAQ:CERC) and Amicus Therapeutics Inc. (NASDAQ:FOLD) on their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cerecor Inc. 15.58M 13.12 41.68M -1.05 0.00
Amicus Therapeutics Inc. 73.33M 32.59 340.12M -1.89 0.00

Table 1 highlights Cerecor Inc. and Amicus Therapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 has Cerecor Inc. and Amicus Therapeutics Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cerecor Inc. -267.52% -164.9% -63.2%
Amicus Therapeutics Inc. -463.82% -73.6% -43%

Liquidity

The Current Ratio of Cerecor Inc. is 0.7 while its Quick Ratio stands at 0.7. The Current Ratio of rival Amicus Therapeutics Inc. is 9.1 and its Quick Ratio is has 9. Amicus Therapeutics Inc. is better equipped to clear short and long-term obligations than Cerecor Inc.

Analyst Ratings

The next table highlights the delivered recommendations and ratings for Cerecor Inc. and Amicus Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Cerecor Inc. 0 0 0 0.00
Amicus Therapeutics Inc. 0 1 3 2.75

On the other hand, Amicus Therapeutics Inc.’s potential upside is 48.13% and its consensus price target is $16.25.

Insider & Institutional Ownership

Roughly 49.9% of Cerecor Inc. shares are owned by institutional investors while 0% of Amicus Therapeutics Inc. are owned by institutional investors. About 4.1% of Cerecor Inc.’s share are owned by insiders. On the other hand, insiders owned about 0.2% of Amicus Therapeutics Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Cerecor Inc. -4.56% -25.39% -27.02% -20.62% 105.53% 4.69%
Amicus Therapeutics Inc. -3.89% -7.01% -11.58% -30.83% -17.72% -26.27%

For the past year Cerecor Inc. has 4.69% stronger performance while Amicus Therapeutics Inc. has -26.27% weaker performance.

Summary

Amicus Therapeutics Inc. beats Cerecor Inc. on 6 of the 11 factors.

Cerecor Inc., a clinical-stage biopharmaceutical company, develops drugs to treat patients with neurological and psychiatric disorders. It develops CERC-501, which has completed Phase II clinical trial for the adjunctive treatment of major depressive disorder (MDD), as well as to treat substance use disorders; CERC-301 that has completed Phase II clinical trial for the adjunctive treatment of patients with MDD; and CERC-406 that is in preclinical stage to treat residual cognitive impairment symptoms in patients with MDD. Cerecor Inc. also intends to develop CERC-611, a drug candidate for the treatment of partial-onset seizures in epilepsy. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Baltimore, Maryland.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies. The company is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease. It is conducting a Phase 1/2 clinical study of ATB200-02 to investigate pompe treatment paradigm in pompe patients. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.